Reagila ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 21 | ミトコンドリア病 | 1 |
21. ミトコンドリア病
臨床試験数 : 33 / 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-001268-58-HU (EUCTR) | 06/07/2021 | 21/03/2021 | Investigation of effects of cariprazine in patients with mitochondrial schizophrenia | Investigation of cellbiological effects of cariprazine in patients with mitochondrial schizophrenia | Mitochondrial disease associated schizophrenia MedDRA version: 20.0;Level: PT;Classification code 10039626;Term: Schizophrenia;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | Trade Name: Reagila Product Name: Reagila | Semmelweis University, STIA-POC-2020 | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Phase 4 | Hungary |